Australia's Therapeutic Goods Administration (TGA) has today given Keytruda® (pembrolizumab) provisional approval for patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) bowel cancer.
A new treatment for advanced bowel cancer has been approved by the Therapeutic Goods Administration (TGA) after demonstrating it could significantly improve overall survival in patients.
Stivarga (regorafenib) has been approved for use in patients who have previously been treated with chemotherapy and who are no longer responding to or not eligible for treatment with other existing drugs such as Avastin and Erbitux.
Australia's Therapeutic Goods Administration (TGA) has today registered Zaltrap® (aflibercept rch), a new treatment for advanced bowel cancer patients.
The medication is proposed to be available for advanced bowel cancer patients in combination with chemotherapy treatment, FOLFIRI. These patients will have previously been treated with another chemotherapy regimen containing oxaliplatin.